{
  "authors": [
    {
      "author": "Shupeng Wen"
    },
    {
      "author": "Zhiyun Niu"
    },
    {
      "author": "Lina Xing"
    },
    {
      "author": "Ying Wang"
    },
    {
      "author": "Hang Li"
    },
    {
      "author": "Na Kuang"
    },
    {
      "author": "Jianmin Luo"
    },
    {
      "author": "Xuejun Zhang"
    },
    {
      "author": "Fuxu Wang"
    }
  ],
  "doi": "10.1186/s12885-018-5037-7",
  "publication_date": "2018-11-22",
  "id": "EN112907",
  "url": "https://pubmed.ncbi.nlm.nih.gov/30458755",
  "source": "BMC cancer",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "In the present study, we report a relapsed adult B-cell ALL case that achieved CR2 after treatment with CD19-directed chimeric antigen receptor (CAR)-modified T cell (CAR-T) therapy. After subsequent allo-HSCT, the patient acquired 21Â months of disease-free survival."
}